REGENXBIO Reports Second Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • 08/06/26
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • 08/03/26
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingPRNewsWire • 07/18/26
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded WarrantsPRNewsWire • 07/17/26
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million MilestonePRNewsWire • 06/29/26
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD FilingSeeking Alpha • 06/28/26
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026PRNewsWire • 06/24/26
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS IIZacks Investment Research • 06/23/26
Regenxbio: Duchenne Data Keeps Me Bullish, There's Less Room For Setbacks NowSeeking Alpha • 06/22/26
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS IIPRNewsWire • 06/22/26
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/22/26
REGENXBIO Reports First Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • 05/14/26